The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 20, 2022
Filed:
Dec. 02, 2016
Agenus Inc., Lexington, MA (US);
Memorial Sloan-kettering Cancer Center, New York, NY (US);
Ludwig Institute for Cancer Research Ltd., Zurich, CH;
Nicholas S. Wilson, Somerville, MA (US);
Jeremy D. Waight, Everett, MA (US);
Gerd Ritter, New York, NY (US);
David Schaer, Mamaroneck, NY (US);
Daniel Hirschhorn-Cymerman, New York, NY (US);
Taha Merghoub, Jersey City, NJ (US);
Ekaterina V. Breous-Nystrom, Basel, CH;
Volker Seibert, Lörrach, DE;
Takemasa Tsuji, Williamsville, NY (US);
Olivier Léger, Saint-Sixt, FR;
Dennis J. Underwood, Jamaica Plain, MA (US);
Marc Van Dijk, Bilthoven, NL;
Agenus Inc., Lexington, MA (US);
Memorial Sloan-Kettering Cancer Center, New York, NY (US);
Ludwig Institute for Cancer Research Ltd., Zurich, CH;
Abstract
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.